- Companies
- Reprieve Cardiovascular
Reprieve Cardiovascular Valuation, Funding & Investors
Reprieve Cardiovascular is valued at $370M as of August 2025.
Last Reprieve Cardiovascular valuation
$370M
Series B · Aug 2025
Last Reprieve Cardiovascular funding round
$61M
Series B · Aug 2025
Cumulative funding Reprieve Cardiovascular raised
$183M
across 7 funding rounds
Key investors in Reprieve Cardiovascular
Deerfield
Sante Ventures
Arboretum Ventures
Lightstone Ventures
Genesis Capital
Rex Health Ventures
About Reprieve Cardiovascular
Reprieve Cardiovascular is a Minnetonka-headquartered medical device company developing fluid management systems for congestive heart failure. Its Reprieve technology enables precise ultrafiltration during dialysis to decongest acute decompensated patients. As a subsidiary of CardioRenal Systems, it advances clinical trials for cardiac care integration.
Founded
2018
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$370M (Aug 2025)
Reprieve Cardiovascular Valuation
Reprieve Cardiovascular is currently valued at $370M, based on its Series B in August 2025.
The $61M round was led by Deerfield, with participation from Lightstone Ventures, Cadence Healthcare Ventures, Rex Health Ventures, Arboretum Ventures, Sante Ventures and 1 other investor.
Reprieve Cardiovascular's valuation has grown 1.2x from $300M at its Series A in November 2023 to $370M in August 2025, across 3 priced rounds.
Reprieve Cardiovascular valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Aug 2025 | Series B | $370M |
| Jun 2025 | Series B | $300M |
| Nov 2023 | Series A | $300M |
Reprieve Cardiovascular Funding History
Reprieve Cardiovascular has raised a total of $183M across 7 funding rounds.
Reprieve Cardiovascular's first fundraising round was a $7M Series A in September 2018. The most recent completed round was a $61M Series B in August 2025.
Reprieve Cardiovascular funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Aug 2025 | Series B | Deerfield (lead); Lightstone Ventures; Cadence Healthcare Ventures; Rex Health Ventures; Arboretum Ventures; Sante Ventures; Genesis Capital | $61M | $370M | Reprieve Cardiovascular is a clinical-stage medtech company founded in 2019 and headquartered in Minneapolis, MN (with operations noted in Milford, Mass.), developing personalized heart failure therapies, specifically the Reprieve System for intelligent decongestion management in acute decompensated heart failure (ADHF). The system addresses challenges in fluid and sodium removal through precise diuretic administration, integrating real-time physiological monitoring with automated recommendations to customize treatment and reduce risks like kidney injury, prolonged hospital stays, and readmissions. The company closed an oversubscribed $61 million Series B financing on August 13, 2025, led by Deerfield Management, with participation from Arboretum Ventures, Cadence Healthcare Ventures (noted as Cadence Capital), Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, and an undisclosed strategic investor. The round combined equity and debt to fund the global FASTR II pivotal clinical trial, which enrolled its first patient at Washington University School of Medicine in St. Louis, aiming to evaluate the Reprieve System against optimal diuretic therapy in up to 400 patients across the US and Europe for future US premarket approval, plus commercial readiness activities. A SalesTools report lists the valuation at $370M post-round. This follows a $42 million Series A in 2024 used for earlier heart failure technology trials, including the completed FASTR randomized pilot study that met primary efficacy and safety endpoints. The funding supports accelerating product development, market expansion, scaling teams, and strengthening positioning in the medtech sector, where investor interest remains high for innovative cardiovascular solutions. CEO Mark Pacyna highlighted the capital's role in generating clinical and economic evidence for regulatory approval and commercialization to improve patient and healthcare system outcomes. |
| Jun 2025 | Series B | - | $31M | $300M | Reprieve Cardiovascular is a clinical-stage HealthTech company based in Milford, MA, founded in 2018, developing the Reprieve System, an intelligent decongestion management therapy for acute decompensated heart failure (ADHF). The system aims to personalize fluid and sodium removal through precise diuretic administration, addressing unmet needs in heart failure treatment by improving patient outcomes over standard diuretic therapy. The company closed an oversubscribed $61 million Series B financing around May-June 2025 (announced August 13, 2025), combining equity and debt, led by Deerfield Management with participation from Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, Cadence Capital, and an undisclosed strategic investor. One source reports the round reached a $300M valuation, while a post-round metric lists current valuation at $100M as of June 4, 2025; total funding raised to date approximately $103M including prior $42M Series A in 2024. Funds support the global FASTR II pivotal clinical trial (first patient enrolled), enrolling up to 400 patients in the US and Europe to evaluate efficacy versus optimal diuretic therapy for FDA premarket approval, plus commercial readiness activities. The FASTR II trial follows the successful FASTR pilot study meeting primary efficacy and safety endpoints. With 70+ employees, Reprieve plans to accelerate product development, expand its team, and scale operations globally. Investors highlight the company's clinical data and potential for better patient and healthcare system outcomes in cardiometabolic care. |
| Feb 2024 | Series A | Lightstone Ventures (lead); Sante Ventures (lead); Arboretum Ventures; Genesis Capital; Deerfield | $42M | - | Reprieve Cardiovascular, a development-stage medtech company based in Milford, Massachusetts, emerged from stealth in February 2024 with a $42 million Series A financing round co-led by Lightstone Ventures and Sante Ventures, with participation from Deerfield Management, Genesis Capital, and Arboretum Ventures. The funding supports advancement of clinical programs, including the ongoing FASTR pilot trial comparing the Reprieve Decongestion Management System—an intelligent automated diuretic and fluid management platform—to standard diuretic therapy for acute decompensated heart failure (ADHF) patients, as well as preparation for a pivotal trial. The Reprieve System aims to personalize decongestion by providing physicians with visibility and control over fluid and sodium removal, targeting improved patient outcomes, reduced hospital readmissions, shorter stays, and enhanced comfort amid over 1 million annual U.S. ADHF hospitalizations from 6.7 million heart failure patients. Heart failure affects over 25 million patients globally, with ADHF representing a high-cost burden due to frequent readmissions. Reprieve's technology seeks to address unmet needs in decongestion management, building on preclinical and early clinical progress initiated in 2022. In a subsequent development, Reprieve raised an oversubscribed $61 million Series B in August 2025 led by Deerfield Management, with existing investors including Arboretum, Lightstone, Sante, and Genesis, plus new participants like Rex Health Ventures and Cadence Capital, plus debt; this funded the FASTR II pivotal trial, which enrolled its first patient after the FASTR pilot met efficacy and safety endpoints, and commercial readiness. |
| Nov 2023 | Series A | - | $12M | $300M | Reprieve Cardiovascular develops therapy for acute decompensated heart failure, focusing on intelligent decongestion management to remove excess fluid and sodium through precise diuretic administration. The company emerged from stealth in February 2024 with a $42 million Series A financing co-led by Lightstone Ventures and Sante Ventures, joined by Deerfield Management, Genesis Capital, and Arboretum Ventures, to advance clinical programs including the FASTR trial. A $61 million oversubscribed Series B round closed in August 2025, led by Deerfield Management with participation from Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, Cadence Capital, and an undisclosed strategic investor, combining equity and debt. One source lists a $300 million valuation for this Series B, while another notes a Series A tranche in November 2023. The Series B funds support the global FASTR II pivotal clinical trial, which enrolled its first patient, and commercial readiness activities following the successful FASTR pilot study. |
| Jun 2022 | Series A | - | $15M | - | - |
| Aug 2020 | Series A | Deerfield (lead) | $15M | - | - |
| Sep 2018 | Series A | Abiomed (lead) | $7M | - | Reprieve Cardiovascular, a Milford, Mass.-based affiliate of RenalGuard Solutions, develops devices for patients with acute decompensated heart failure using Guided Diuretic Therapy to speed decongestion, protect organ function, shorten hospital stays, and reduce re-hospitalizations. The company closed a $7 million financing round joined by Abiomed to support its formation and development. Reprieve debuted its technology at Heart Failure 2018, presenting late-breaking clinical trial data and hosting a satellite symposium, with CEO Jim Dillon noting strong interest. |
Who has invested in Reprieve Cardiovascular?
8 investors have backed Reprieve Cardiovascular across its funding rounds, including Deerfield, Sante Ventures, Arboretum Ventures, Lightstone Ventures, Genesis Capital and Rex Health Ventures.
Lead investors include Deerfield, Lightstone Ventures, Sante Ventures and Abiomed.
Reprieve Cardiovascular Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Aug 2020 | ||
| 2 | Lead | Feb 2024 | ||
| 2 | Participant | Feb 2024 | ||
| 2 | Lead | Feb 2024 | ||
| 2 | Participant | Feb 2024 | ||
| 1 | Participant | Aug 2025 | ||
This data is available for Pro users. Sign up to see all 8 Reprieve Cardiovascular investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialReprieve Cardiovascular Competitors
Reprieve Cardiovascular competitors include listed companies like Myriad Genetics and Orchestra BioMed, and private ones like Cloudnine Hospitals, InSightec, Selkirk Pharma and InnerMedical.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $101M | - | $321M | 3.2x | ||
| Publicly listed | $825M | ($332M) | $372M | 0.6x | ||
| Private | $14M | - | $375M | 26.8x | ||
| Private | - | - | $375M | - | ||
| Publicly listed | $33M | ($51M) | $365M | 30.8x | ||
| Private | - | - | $363M | - |
Reprieve Cardiovascular Public Comps
Reprieve Cardiovascular is still privately-owned, but its public comps include NIOX Group, Myriad Genetics, Sofwave Medical, Orchestra BioMed, Auna, Shoulder Innovations, IVF hartmann, Universal Vision, CapsoVision and Orthofix Medical.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65M | $20M | 5.3x | 5.2x | 17.4x | 15.0x | |||
| $825M | ($332M) | 0.6x | 0.6x | (1.4x) | (15.9x) | |||
| $88M | $7M | 3.9x | - | 48.7x | - | |||
| $33M | ($51M) | 9.0x | 30.8x | (5.9x) | (3.7x) | |||
| $1.3B | $249M | 1.0x | 1.0x | 5.5x | 5.0x | |||
| $47M | ($37M) | 6.2x | 4.7x | (7.9x) | (8.7x) | |||
| $196M | $32M | 1.2x | - | 7.2x | - | |||
| $132M | $58M | 2.8x | 2.7x | 6.4x | - | |||
This data is available for Pro users. Sign up to see all Reprieve Cardiovascular competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Reprieve Cardiovascular
| When was Reprieve Cardiovascular founded? | Reprieve Cardiovascular was founded in 2018. |
| Where is Reprieve Cardiovascular headquartered? | Reprieve Cardiovascular is headquartered in Boston, MA, United States. |
| Is Reprieve Cardiovascular publicly listed? | No, Reprieve Cardiovascular is a private, VC-backed company. |
| What is Reprieve Cardiovascular's valuation? | Reprieve Cardiovascular was last valued at $370M in its Series B in August 2025. |
| How much funding has Reprieve Cardiovascular raised? | Reprieve Cardiovascular has raised $183M across 7 funding rounds. |
| What was Reprieve Cardiovascular's last funding round? | Reprieve Cardiovascular's last funding round was a $61M Series B in August 2025, led by Deerfield. |
| Who are Reprieve Cardiovascular's investors? | Reprieve Cardiovascular's investors include Deerfield, Lightstone Ventures, Arboretum Ventures, Sante Ventures, Genesis Capital, Cadence Healthcare Ventures, Rex Health Ventures and Abiomed. |
| Which companies are comparable to Reprieve Cardiovascular? | Companies comparable to Reprieve Cardiovascular include Cloudnine Hospitals, Myriad Genetics, InSightec, Selkirk Pharma, Orchestra BioMed and InnerMedical. |
See companies similar to Reprieve Cardiovascular
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




